Brind.

Market volatility was observed in the health sector, driven by Sarepta's gene therapy trials being halted by the FDA due to patient liver failure, alongside broader market concerns affecting the S&P index.

1 report, 1 independent Updated Jul 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Sarepta Food and Drug Administration S&P

Keep exploring

The entities involved

Sarepta
Nothing else this week.
Food and Drug Administration
government organization in Nonthaburi, Thailand
- Trump is expected to nominate Heidi Overton to lead the Food and Drug Administration.Mon 15:49
- In 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Mon 12:46
S&P
Japanese company
- Buffett mentioned S&P as a historical information source, and Robert R. Johnson is a professor at Creighton University.Sun 12:13
- Automated Insights reported that AES is based in Arlington and shares performance metrics compared to the S&P 500.Sun 09:11

Coverage

Newest first; wire copies grouped

Jul 25TheStreetStock Market Today: S&P 500 Notches Fifth Consecutive Record Close as Vanguard, Goldman Warn On Growth Stock Market Today: S&P 500 Notches Fifth Consecutive Record Close as Vanguard, Goldman Warn On